Back to Browse Journals » Vascular Health and Risk Management » Volume 7

Pre-eclampsia: pathophysiology, diagnosis, and management

Authors Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi J-M

Published 19 July 2011 Volume 2011:7 Pages 467—474


Review by Single-blind

Peer reviewer comments 3

Jennifer Uzan1, Marie Carbonnel1, Olivier Piconne1,3, Roland Asmar2, Jean-Marc Ayoubi1
1Department of Gynecology and Obstetrics, Hôpital Foch, Suresnes, France; 2Foundation Medical Research Institutes, Geneva, Switzerland; 3Department of Gynecology and Obstetrics, Hôpital Antoine Béclère, Clamart, France

Abstract: The incidence of pre-eclampsia ranges from 3% to 7% for nulliparas and 1% to 3% for multiparas. Pre-eclampsia is a major cause of maternal mortality and morbidity, preterm birth, perinatal death, and intrauterine growth restriction. Unfortunately, the pathophysiology of this multisystem disorder, characterized by abnormal vascular response to placentation, is still unclear. Despite great polymorphism of the disease, the criteria for pre-eclampsia have not changed over the past decade (systolic blood pressure >140 mmHg or diastolic blood pressure ≥90 mmHg and 24-hour proteinuria ≥0.3 g). Clinical features and laboratory abnormalities define and determine the severity of pre-eclampsia. Delivery is the only curative treatment for pre-eclampsia. Multidisciplinary management, involving an obstetrician, anesthetist, and pediatrician, is carried out with consideration of the maternal risks due to continued pregnancy and the fetal risks associated with induced preterm delivery. Screening women at high risk and preventing recurrences are key issues in the management of pre-eclampsia.

Keywords: pre-eclampsia, epidemiology, pathophysiology, therapeutic management

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Short-term outcome of patients with preeclampsia

Koual M, Abbou H, Carbonnel M, Picone O, Ayoubi JM

Vascular Health and Risk Management 2013, 9:143-148

Published Date: 15 April 2013

Readers of this article also read:

Dabigatran and myocardial infarction: a foggy scenario

Pontillo D, Patruno N

Vascular Health and Risk Management 2014, 10:45-48

Published Date: 20 January 2014

The interblink interval in normal and dry eye subjects

Johnston PR, Rodriguez J, Lane KJ, Ousler G, Abelson MB

Clinical Ophthalmology 2013, 7:253-259

Published Date: 1 February 2013

A novel, efficient CNTFET Galois design as a basic ternary-valued logic field

Keshavarzian P, Mirzaee MM

Nanotechnology, Science and Applications 2012, 5:1-11

Published Date: 24 January 2012

Validation of four automatic devices for self-measurement of blood pressure according to the international protocol of the European Society of Hypertension

Topouchian J, Agnoletti D, Blacher J, Youssef A, Ibanez I, Khabouth J, Khawaja S, Beaino L, Asmar R

Vascular Health and Risk Management 2011, 7:709-717

Published Date: 30 November 2011

Telmisartan and cardioprotection

Akhrass PR, McFarlane SI

Vascular Health and Risk Management 2011, 7:677-683

Published Date: 15 November 2011

Risk factors for primary open-angle glaucoma in Japanese subjects attending community health screenings

Ishikawa M, Sawada Y, Sato N, Yoshitomi T

Clinical Ophthalmology 2011, 5:1531-1537

Published Date: 20 October 2011

Novel drug-eluting stents in the treatment of de novo coronary lesions

Davide Capodanno, Fabio Dipasqua, Corrado Tamburino

Vascular Health and Risk Management 2011, 7:103-118

Published Date: 25 February 2011

Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation

Banny S Wong, Noriaki Manabe, Michael Camilleri

Clinical and Experimental Gastroenterology 2010, 3:49-56

Published Date: 24 May 2010

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies

Jorge Castillo, Kimberly Perez

Journal of Blood Medicine 2010, 1:1-8

Published Date: 25 February 2010


Dove Medical Press Editorial

Clinical Interventions in Aging 2008, 3:397-397

Published Date: 6 June 2008